What it sells
Clinical trial matching sold to insurers.
Business model breakdown
Buyer: who owns the budget?
UnverifiedPayers and employers (benefits/medical management), pharma sponsors' clinical teams.
Trigger: what makes them buy now?
Compounding cancer claims costs and patients lost out of network.
Workflow: what inputs become what output?
Pre-screen existing patient populations, refer to open trials, then Navigation OS addresses transport, food, language and scheduling barriers through completion.
Economics: what it saves and how it charges
Multi-sided: sponsors pay to reach pre-qualified patients; payers/employers pay for navigation; claims a 35% reduction in patients lost to other health systems.
Distribution: how it reaches customers
Demo-led (Schedule Demo) plus provider research network.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2025-12-02 | — | $10M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.